

## Multifocal Bullous Fixed Drug Eruption

### Eritema Pigmentado Fixo Bolhoso

Carolina OLIVEIRA<sup>1</sup>, Maria Alexandra RODRIGUES<sup>2</sup>, Glória CUNHA VELHO<sup>2,3,4</sup>  
*Acta Med Port* 2023 May;36(5):361-362 • <https://doi.org/10.20344/amp.16519>

**Keywords:** Drug Eruptions; Etoricoxib; Non-steroidal Anti-inflammatory Drugs; Skin Diseases

**Palavras-chave:** Anti-inflamatórios Não Esteróides; Doenças da Pele; Erupções por Medicamento; Etoricoxib; Medicamentosa



Figure 1 – Round, well circumscribed, edematous erythematous-violaceous plaque

We report a case of a 58-year-old woman with multiple round, well circumscribed, edematous erythematous-violaceous plaques on the trunk and both upper and lower limbs (Figs. 1 and 2) which appeared about 24 hours after taking etoricoxib for dental pain. She denied taking other drugs. She mentioned a similar episode in the past, after etoricoxib as well. The biopsy confirmed the diagnosis, but the patch test with etoricoxib on the lesional skin was negative.

Multifocal bullous fixed drug eruption is an adverse drug reaction that is characterized by multiple plaques with frequently central bullous detachment.<sup>1,2</sup> They can be located anywhere on the body surface, including on the genitalia and oral mucosa. The lesions appear several days after the intake of the drug, but can emerge in less than 24 hours on



Figure 2 – Multiple lesions on the trunk and lower limbs

the same anatomical sites, if there is a re-exposure. The most common culprit agents are non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics.<sup>3</sup>

#### AUTHOR CONTRIBUTIONS

CRO, GCV: Clinical history, draft of the paper.

MAR: Clinical history, draft of the paper, images.

#### PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in 2013.

1. Unidade de Saúde Familiar Sem Fronteiras. Agrupamento de Centros de Saúde Entre Douro e Vouga I Feira/Arouca. Santa Maria da Feira. Portugal.

2. Serviço de Dermatologia. Centro Hospitalar e Universitário do Porto. Porto. Portugal.

3. Instituto de Ciências Biomédicas Abel Salazar. Porto. Portugal.

4. Unidade de Investigação de Dermatologia. Centro Hospitalar e Universitário do Porto. Porto. Portugal.

✉ Autor correspondente: Carolina Oliveira. [oliveira.carolina91@gmail.com](mailto:oliveira.carolina91@gmail.com)

Recebido/Received: 08/05/2021 - Aceite/Accepted: 21/01/2022 - Publicado Online/Published Online: 28/02/2022 - Publicado/Published: 02/05/2023

Copyright © Ordem dos Médicos 2023



### DATA CONFIDENTIALITY

The authors declare having followed the protocols in use at their working center regarding patients' data publication.

### PATIENT CONSENT

Obtained.

### COMPETING INTERESTS

The authors have declared that no competing interests exist.

### FUNDING SOURCES

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### REFERENCES

1. Chugh S, Sarkar R, Garg VK, Singh A, Keisham C. Multifocal fixed drug eruption with COX-2 inhibitor celecoxib. *Indian J Dermatol.* 2013;58:142-4.
2. Carneiro-Leão L, Cernadas J. Bullous fixed drug eruption caused by etoricoxib confirmed by patch testing. *J Allergy Clin Immunol Pract.* 2019;7:1629-30.
3. Sousa AS, Cardoso JC, Gouveia MP, Gameiro AR, Teixeira VB, Gonçalo M. Fixed drug eruption by etoricoxib confirmed by patch test. *An Bras Dermatol.* 2016;91:652-4.
4. Antunes J, Prates S, Leiria-Pinto P. Fixed drug eruption due to etoricoxib - a case report. *Allergol Immunopathol.* 2013;42:623-4.
5. Gómez dela Fuente E, Pampín Franco A, Caro Gutiérrez D, López Estebanz J. Exantema fijo medicamentoso por etoricoxib con tolerancia a celecoxib. Utilidad de las pruebas epicutáneas. *Actas Dermosifiliogr.* 2014;105:314-5.